Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

被引：36

作者：

Mendes, Rodrigo E. ^{[1
]}

Flamm, Robert K. ^{[1
]}

Hogan, Patricia A. ^{[2
]}

Ross, James E. ^{[1
]}

Jones, Ronald N. ^{[1
,3
]}

机构：

[1] JMI Labs, North Liberty, IA USA

[2] Pfizer Inc, Collegeville, PA USA

[3] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 02期

关键词：

STAPHYLOCOCCUS-AUREUS; SPECTRUM ANALYSIS; RIBOSOMAL-RNA; VANCOMYCIN; BACTEREMIA; STRAIN; GENE;

D O I：

10.1128/AAC.02112-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This study summarizes the linezolid susceptibility testing results for 7,429 Gram-positive pathogens from 60 U.S. sites collected during the 2012 sampling year for the LEADER Program. Linezolid showed potent activity when tested against 2,980 Staphylococcus aureus isolates, inhibiting all but 3 at <= 2 mu g/ml. Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000.

引用

页码：1243 / 1247

页数：5

共 22 条

[21] Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections [J].